Nuage Therapeutics SL has appointed Stuart Hughes as chief executive officer and Vanessa Malier as chair of the board. The Spanish biotech has developed tools enabling the capture of ‘disordered’ proteins in a form that is amenable to small molecule drug discovery. It is focused on precision therapies by targeting oncogenic transcription factors. Dr Hughes joins Nuage from Pathios Therapeutics, an immuno-oncology company where he was CEO. Previously he was a senior director at Vertex Pharmaceuticals and a principal research scientist in CNS disorders at Eli Lilly. Dr Hughes has a PhD in neuroscience from Cardiff University, UK. Ms Malier is a board member and advisor to biotechs, venture capital and private equity firms, and is currently a non-executive director of Sygnature Discovery.
Nuage announced the appointments on 1 April 2025.
Copyright 2025 Evernow Publishing Ltd.